Prosecution Insights
Last updated: November 12, 2026
Application No. 18/900,302

AQUEOUS FIBROIN SOLUTION AND PRODUCTION METHOD THEREOF, AND ARTICLE COMPRISING FIBROIN

Non-Final OA §102§103§112
Filed
Sep 27, 2024
Priority
Mar 31, 2022 — JP 2022-060225 +2 more
Examiner
ELHILO, EISA B
Art Unit
1761
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Canon Virginia Inc.
OA Round
1 (Non-Final)
83%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allowance Rate
1214 granted / 1463 resolved
+18.0% vs TC avg
Strong +16% interview lift
Without
With
+16.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
46 currently pending
Career history
1510
Total Applications
across all art units

Office Action

§102 §103 §112
Claims 1 and 4-15 are pending in this application. DETAILED ACTION Notice of Pre-AIA or AIA Status 1 The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2 This action is responsive to the applicant’s election without traverse received by the office on October 12, 2026. Election of claims 1, 4-9 and the newly added claim 15 is acknowledged. Claims 10-14 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention. Therefore, claims 1, 4-9 and 15 are pending in this application. Claim Objections 3 Claim 1 objected to because of the following informalities: Claim 1 is not ended with a period. Claim 1 should be ended with a period at the end of the claim. Appropriate correction is required. Claim Rejections - 35 USC § 112 4 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 5-8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 5 and 6 recite the limitations “the general formula (1) is any one selected from a tetraalkylammonium halide, and a halide, hydroxide, or carboxylate of any one selected from chloride, a choline derivative, glycine and a glycine derivative”. It is unclear what the chemical name of the compound that represented by the claimed formula (1)? And also, it is unclear what the counter anion X- represents? Is it representing halide, choline, glycine or a glycine derivative? Clarification and/or correction are/is required. Claim 7 recites the limitation “molecular weight of 100,000 or more”. It is unclear what the unit used for the claimed molecular weight of the fibroin? Correction is required. Claim 8 recites the limitation “wherein the fibroin has a concentration of from 5 mass% to 40 mass%”. It is unclear if the mass % with respect to the total mass of the aqueous solution? or with respect to the total mass of the fibroin?. Clarification is required. Claim Rejections - 35 USC § 102 5 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. 6 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 4-9 are rejected under 35 U.S.C. 102(a)1 as being anticipated by Wang et al., (CN 113603901 A). English translation of the Patent No. (CN 113603901 A) is used in this Office action. Wang et al., (CN’ 901 A) teaches an aqueous solution comprising silk fibroin and quaternary ammonium compound include tetraethyl ammonium hydroxide that reads on the claimed formula (I), when in the claimed formula (I), R1 to R4 are alkyl groups and X- is hydroxide group as claimed in claims 1, 4-6 and 9 (see English abstract), and wherein the fibroin has a concentration of 23.56 wt.% as claimed in claim 8 (see page 14, Fig. 7-9). Wang et al., (CN’ 901 A) teaches a silk fibroin identical to claimed silk fibroin which inherently should have same molecular weight as those claimed in claim 7. Wang et al., (CN’ 901 A) teaches all the limitations of the instant claims. Hence, Wang et al., (CN’ 901 A) anticipates the claims. Claim Rejections - 35 USC § 103 7 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 15 is rejected under 35 U.S.C. 103 as being unpatentable over Wang et al., (CN 113603901 A). English translation of the Patent No. (CN 113603901 A) is used in this Office action. Wang et al., (CN’ 901 A) teaches an aqueous solution comprising silk fibroin and quaternary ammonium compound include tetraethyl ammonium hydroxide that reads on the claimed formula (I), when in the claimed formula (I), R1 to R4 are alkyl groups and X- is hydroxide group as claimed (see English abstract). The instant claims differ from the teaching of Wang et al., (CN’ 901 A) by reciting the amount of the compound represented by the claimed formula (I) to be in an amount of from 0.1 mass% to 50 mass% with respect to a mass of the fibroin dissolved in the aqueous solution. However, Wang et al., (CN’ 901 A) clearly teaches the concentration of the quaternary ammonium alkali aqueous solution is 0.5 to 4.0M (see English abstract). Therefore, in view of the teaching of Wang et al., (CN’ 901 A), it would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention, to optimize the amount of the quaternary ammonium compounds in the aqueous solution in order to get the maximum effective amounts of these compounds, and, thus, the person of the ordinary skill in the art would expect such an aqueous composition to have similar results to those claimed, absent unexpected results. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to EISA B ELHILO whose telephone number is (571)272-1315. The examiner can normally be reached Monday-Friday, 7:00 AM to 3:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Angela Brown-Pettigrew can be reached at (571)272-2817. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /EISA B ELHILO/Primary Examiner, Art Unit 1761
Read full office action

Prosecution Timeline

Sep 27, 2024
Application Filed
Oct 23, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790568
Alkyl Sulfonic Acid Compositions Comprising Solvent Useful in Descaling Applications
2y 4m to grant Granted Nov 10, 2026
Patent 12779364
NANOFLUID COMPOSITION FOR DISPLACEMENT OF ENTRAINED CONTAMINANTS FROM RESTRICTED GEOMETRIES AND CAPILLARY FEATURES
2y 6m to grant Granted Nov 03, 2026
Patent 12782770
METHOD FOR MANUFACTURING SUCH A DISPLAY SCREEN
2y 0m to grant Granted Nov 03, 2026
Patent 12773650
ENHANCED EXTRACTION OF NATURAL PRODUCTS FROM BIOMASS
3y 4m to grant Granted Oct 27, 2026
Patent 12768098
METHOD FOR PRODUCING CARBAMATED CELLULOSE FIBERS
2y 8m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
83%
Grant Probability
99%
With Interview (+16.2%)
Low
PTA Risk
Based on 1463 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month